Skip to main
BIOX
BIOX logo

BIOX Stock Forecast & Price Target

BIOX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bioceres Crop Solutions is projecting FY24 revenues of $464.8 million, representing an 11% year-over-year growth, driven by a significant 46% growth in HB4 sales and improved applications in crop protection. The company anticipates approximately 20% annual EBITDA growth, supported by the expansion of HB4 Soy acreage in Brazil and increasing manufacturing capabilities in crop protection and nutrition, which will enhance margins from 20% to the target of 25%. Additionally, with a robust crop productivity franchise and opportunities for geographic expansion, Bioceres expects mid-teens organic growth and a shift towards mid-20% AEBITDA margins, particularly fueled by the adoption of drought-resistant seed technologies in the large Brazilian market.

Bears say

Bioceres Crop Solutions Corp faces a challenging financial landscape characterized by a revision of growth expectations, with the company now projecting mid-teens growth, down from prior targets of over 20%. The decreased adjusted EBITDA performance, primarily due to elevated operating expenses and a decline in key revenue sources such as the Syngenta accrual, has contributed to a negative outlook on profitability. Additionally, industry challenges have led to a decrease in gross margins and ongoing concerns regarding the viability of the company's low-margin grain sales impacting overall financial results.

BIOX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bioceres Crop Solutions Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bioceres Crop Solutions Corp (BIOX) Forecast

Analysts have given BIOX a Strong Buy based on their latest research and market trends.

According to 5 analysts, BIOX has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bioceres Crop Solutions Corp (BIOX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.